ABSTRACT
Thin melanomas (Breslow s depth <1.0 mm) have a low propensity to metastasize to regional lymph nodes (<5%). Thus, patients with thin lesions are usually not offered a SLNB unless they have a lesion with one or more adverse prognostic indicators. Such factors are: Clarks level >111, ulceration, evidence of regression, or mitoses >0. All patients with intermediate thickness and thick lesions, with clinically negative nodes (clinical Stage IB and II), are appropriate candidates for SLNB.
